首页 > 最新文献

JAMA ophthalmology最新文献

英文 中文
Predictive Power of Polygenic Risk Scores for Intraocular Pressure or Vertical Cup-Disc Ratio. 多基因风险评分对眼压或垂直杯盘比的预测能力。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamaophthalmol.2024.4856
Weixiong He, Samantha Sze-Yee Lee, Santiago Diaz Torres, Xikun Han, Puya Gharahkhani, Michael Hunter, Chandrakumar Balartnasingam, Jamie E Craig, Alex W Hewitt, David A Mackey, Stuart MacGregor

Importance: Early detection of glaucoma is essential to timely monitoring and treatment, and primary open-angle glaucoma risk can be assessed by measuring intraocular pressure (IOP) or optic nerve head vertical cup-disc ratio (VCDR). Polygenic risk scores (PRSs) could provide a link between genetic effects estimated from genome-wide association studies (GWASs) and clinical applications to provide estimates of an individual's genetic risk by combining many identified variants into a score.

Objective: To construct IOP and VCDR PRSs with clinically relevant predictive power.

Design, setting, and participants: This genetic association study evaluated the PRSs for 6959 of 51 338 individuals in the Canadian Longitudinal Study on Aging (CLSA; 2010 to 2015 with data from 11 centers in Canada) and 4960 of 5107 individuals the community-based Busselton Healthy Aging Study (BHAS; 2010 to 2015 in Busselton, Western Australia) with an artificial intelligence grading approach used to obtain precise VCDR estimates for the CLSA dataset. Data for approximately 500 000 individuals in UK Biobank from 2006 to 2010 were used to validate the power of the PRS. Data were analyzed from June to November 2023.

Main outcomes and measures: IOP and VCDR PRSs and phenotypic variance (R2) explained by each PRS.

Results: Participants in CLSA were aged 45 to 85 years; those in BHAS, 46 to 64 years; and those in UK Biobank, 40 to 69 years. The VCDR PRS explained 22.0% (95% CI, 20.1-23.9) and 19.7% (95% CI, 16.3-23.3) of the phenotypic variance in VCDR in CLSA and BHAS, respectively, while the IOP PRS explained 12.9% (95% CI, 11.3-14.6) and 9.6% (95% CI, 8.1-11.2) of phenotypic variance in CLSA and BHAS IOP measurements. The VCDR PRS variance explained 5.2% (95% CI, 3.6-7.1), 12.1% (95% CI, 7.5-17.5), and 14.3% (95% CI, 9.3-19.9), and the IOP PRS variance explained 2.3% (95% CI, 1.5-3.3), 3.2% (95% CI, 1.3-5.8), and 7.5% (95% CI, 6.2-8.9) (P < .001) across African, East Asian, and South Asian populations, respectively.

Conclusions and relevance: VCDR and IOP PRSs derived using a large recently published multitrait GWAS exhibited validity across independent cohorts. The findings suggest that an IOP PRS has the potential to identify individuals who may benefit from more intensive IOP-lowering treatments, which could be crucial in managing glaucoma risk more effectively. Individuals with a high VCDR PRS may be at risk of developing glaucoma even if their IOP measures fall within the normal range, suggesting that these PRSs could help in early detection and intervention, particularly among those who might otherwise be considered at low risk based on IOP alone.

重要性:早期发现青光眼对及时监测和治疗至关重要,原发性开角型青光眼风险可通过测量眼压(IOP)或视神经头垂直杯盘比(VCDR)来评估。多基因风险评分(PRS)可以将全基因组关联研究(GWAS)估算出的遗传效应与临床应用联系起来,通过将许多已识别的变异组合成一个评分来估算个体的遗传风险:目的:构建具有临床相关预测能力的 IOP 和 VCDR PRS:这项遗传关联研究评估了加拿大老龄化纵向研究(CLSA,2010 年至 2015 年,数据来自加拿大 11 个中心)51 338 名个体中 6959 名个体的 PRSs,以及基于社区的布瑟尔顿健康老龄化研究(BHAS,2010 年至 2015 年,位于西澳大利亚布瑟尔顿)5107 名个体中 4960 名个体的 PRSs。2006 年至 2010 年期间,英国生物库中约 50 万人的数据被用于验证 PRS 的威力。数据分析时间为 2023 年 6 月至 11 月:主要结果和测量指标:眼压和VCDR PRS以及每个PRS解释的表型方差(R2):结果:CLSA 的参与者年龄在 45 至 85 岁之间;BHAS 的参与者年龄在 46 至 64 岁之间;UK Biobank 的参与者年龄在 40 至 69 岁之间。VCDR PRS分别解释了CLSA和BHAS中VCDR表型变异的22.0%(95% CI,20.1-23.9)和19.7%(95% CI,16.3-23.3),而IOP PRS分别解释了CLSA和BHAS IOP测量表型变异的12.9%(95% CI,11.3-14.6)和9.6%(95% CI,8.1-11.2)。VCDR PRS 变异解释了 5.2%(95% CI,3.6-7.1)、12.1%(95% CI,7.5-17.5)和 14.3%(95% CI,9.3-19.9),IOP PRS 变异解释了 2.3%(95% CI,1.5-3.3)、3.2%(95% CI,1.3-5.8)和 7.5%(95% CI,6.2-8.9)(P 结论和相关性:利用最近发表的大型多特征 GWAS 得出的 VCDR 和 IOP PRS 在独立队列中表现出有效性。研究结果表明,眼压 PRS 有可能识别出那些可能从更密集的降低眼压治疗中获益的个体,这对于更有效地管理青光眼风险至关重要。具有高 VCDR PRS 的个体即使其眼压测量值在正常范围内,也可能有罹患青光眼的风险,这表明这些 PRS 有助于早期发现和干预,尤其是在那些仅凭眼压就可能被认为是低风险的人群中。
{"title":"Predictive Power of Polygenic Risk Scores for Intraocular Pressure or Vertical Cup-Disc Ratio.","authors":"Weixiong He, Samantha Sze-Yee Lee, Santiago Diaz Torres, Xikun Han, Puya Gharahkhani, Michael Hunter, Chandrakumar Balartnasingam, Jamie E Craig, Alex W Hewitt, David A Mackey, Stuart MacGregor","doi":"10.1001/jamaophthalmol.2024.4856","DOIUrl":"10.1001/jamaophthalmol.2024.4856","url":null,"abstract":"<p><strong>Importance: </strong>Early detection of glaucoma is essential to timely monitoring and treatment, and primary open-angle glaucoma risk can be assessed by measuring intraocular pressure (IOP) or optic nerve head vertical cup-disc ratio (VCDR). Polygenic risk scores (PRSs) could provide a link between genetic effects estimated from genome-wide association studies (GWASs) and clinical applications to provide estimates of an individual's genetic risk by combining many identified variants into a score.</p><p><strong>Objective: </strong>To construct IOP and VCDR PRSs with clinically relevant predictive power.</p><p><strong>Design, setting, and participants: </strong>This genetic association study evaluated the PRSs for 6959 of 51 338 individuals in the Canadian Longitudinal Study on Aging (CLSA; 2010 to 2015 with data from 11 centers in Canada) and 4960 of 5107 individuals the community-based Busselton Healthy Aging Study (BHAS; 2010 to 2015 in Busselton, Western Australia) with an artificial intelligence grading approach used to obtain precise VCDR estimates for the CLSA dataset. Data for approximately 500 000 individuals in UK Biobank from 2006 to 2010 were used to validate the power of the PRS. Data were analyzed from June to November 2023.</p><p><strong>Main outcomes and measures: </strong>IOP and VCDR PRSs and phenotypic variance (R2) explained by each PRS.</p><p><strong>Results: </strong>Participants in CLSA were aged 45 to 85 years; those in BHAS, 46 to 64 years; and those in UK Biobank, 40 to 69 years. The VCDR PRS explained 22.0% (95% CI, 20.1-23.9) and 19.7% (95% CI, 16.3-23.3) of the phenotypic variance in VCDR in CLSA and BHAS, respectively, while the IOP PRS explained 12.9% (95% CI, 11.3-14.6) and 9.6% (95% CI, 8.1-11.2) of phenotypic variance in CLSA and BHAS IOP measurements. The VCDR PRS variance explained 5.2% (95% CI, 3.6-7.1), 12.1% (95% CI, 7.5-17.5), and 14.3% (95% CI, 9.3-19.9), and the IOP PRS variance explained 2.3% (95% CI, 1.5-3.3), 3.2% (95% CI, 1.3-5.8), and 7.5% (95% CI, 6.2-8.9) (P < .001) across African, East Asian, and South Asian populations, respectively.</p><p><strong>Conclusions and relevance: </strong>VCDR and IOP PRSs derived using a large recently published multitrait GWAS exhibited validity across independent cohorts. The findings suggest that an IOP PRS has the potential to identify individuals who may benefit from more intensive IOP-lowering treatments, which could be crucial in managing glaucoma risk more effectively. Individuals with a high VCDR PRS may be at risk of developing glaucoma even if their IOP measures fall within the normal range, suggesting that these PRSs could help in early detection and intervention, particularly among those who might otherwise be considered at low risk based on IOP alone.</p>","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"15-22"},"PeriodicalIF":7.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance of Polygenic Risk Scores for Primary Open-Angle Glaucoma in Populations of African Descent. 原发性开角型青光眼多基因风险评分在非洲裔人群中的表现。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamaophthalmol.2024.4784
Jennifer M Chang-Wolf, Tyler G Kinzy, Sjoerd J Driessen, Lauren A Cruz, Sudha K Iyengar, Neal S Peachey, Tin Aung, Chiea Chuen Khor, Susan E Williams, Michele Ramsay, Olusola Olawoye, Adeyinka Ashaye, Caroline C W Klaver, Michael A Hauser, Alberta A H J Thiadens, Jessica N Cooke Bailey, Pieter W M Bonnemaijer
<p><strong>Importance: </strong>Primary open-angle glaucoma (POAG) polygenic risk scores (PRSs) continue to be evaluated in primarily European-ancestry populations despite higher prevalence and worse outcomes in African-ancestry populations.</p><p><strong>Objective: </strong>To evaluate how established POAG PRSs perform in African-ancestry samples from the Genetics in Glaucoma Patients of African Descent (GIGA), Genetics of Glaucoma in Individuals of African Descent (GGLAD), and Million Veteran Program (MVP) datasets and compare these with European-ancestry samples.</p><p><strong>Design, setting, and participants: </strong>This was a multicenter, cross-sectional study of POAG cases and controls from Tanzania, South Africa, Nigeria, Ghana, and the US. Included were individuals of African descent from South Africa and Tanzania from the GIGA dataset; individuals of African descent from Ghana, Nigeria, and the US from the GGLAD dataset; and individuals of African or European descent from the US in the MVP dataset. Data were analyzed from January 2022 to July 2023.</p><p><strong>Exposures: </strong>Three PRSs derived from large meta-analyses of European and Asian populations, namely Gharahkhani et al (Gharahkhani PRS), Han et al (Han PRS), and Craig et al (Craig PRS).</p><p><strong>Main outcomes and measures: </strong>Odds ratios (ORs) for POAG risk stratification comparing the highest and lowest quintiles; area under the receiver operating characteristic curve (AUROC), and liability coefficient of determination (R2) for the addition of PRS to a baseline of age, sex, and first 5 principal components.</p><p><strong>Results: </strong>A total of 11 673 cases and 66 432 controls were included in this study across 7 ancestral groups. Mean (SD) age of the total participants was 76.9 (8.7) years, with 74 304 males (95.1%). The following were included in each dataset: GIGA (663 cases, 476 controls), GGLAD (1471 cases, 1482 controls), and MVP (9559 cases, 64 474 controls). Increases in ORs were found for the highest POAG risk quintile ranging from an OR of 1.68 (95% CI, 1.17-2.43) in Ghanaians to 7.05 (95% CI, 2.73-19.6) in the South African multiple ancestry group (which derives from at least 5 distinct ancestral groups: Khoisan, Bantus, Europeans, Indians, and Southeast Asians) with the Gharahkhani PRS. The Han PRS showed OR increases for the highest POAG risk quintile ranging from 2.27 (95% CI, 1.49-3.47) in African American individuals in the GGLAD dataset to 7.24 (95% CI, 6.47-8.12) in Europeans. The Craig PRS predicted OR increases in the highest quintile for all groups ranging from 1.51 (95% CI, 1.05-2.18) in Ghanaians to 6.31 (95% CI, 5.67-7.04) in Europeans. However, AUROC and R2 increases above baseline were lower for all African-ancestry compared with European-ancestry groups in the 3 tested PRSs.</p><p><strong>Conclusions and relevance: </strong>In this cross-sectional study, despite some improvements in OR-based risk stratification using the Ghara
重要性:原发性开角型青光眼(POAG)多基因风险评分(PRSs)仍主要在欧洲裔人群中进行评估,尽管在非洲裔人群中发病率更高且结果更差:目的:评估已建立的 POAG PRS 在非洲裔青光眼患者遗传学(GIGA)、非洲裔青光眼遗传学(GGLAD)和百万退伍军人计划(MVP)数据集中的非洲裔样本中的表现,并与欧洲裔样本进行比较:这是一项多中心横断面研究,研究对象是来自坦桑尼亚、南非、尼日利亚、加纳和美国的 POAG 病例和对照组。研究对象包括 GIGA 数据集中来自南非和坦桑尼亚的非洲后裔;GGLAD 数据集中来自加纳、尼日利亚和美国的非洲后裔;MVP 数据集中来自美国的非洲或欧洲后裔。数据分析时间为 2022 年 1 月至 2023 年 7 月:三个PRS来自欧洲和亚洲人群的大型荟萃分析,即Gharahkhani等人(Gharahkhani PRS)、Han等人(Han PRS)和Craig等人(Craig PRS):主要结果和测量指标:比较最高和最低五分位数的 POAG 风险分层的比率(ORs);接收者操作特征曲线下面积(AUROC);在年龄、性别和前 5 个主成分的基线上增加 PRS 的责任决定系数(R2):本研究共纳入 11 673 例病例和 66 432 例对照,涉及 7 个祖先群体。所有参与者的平均年龄(标准差)为 76.9(8.7)岁,其中男性 74 304 人(95.1%)。每个数据集包括以下内容:GIGA(663 例,476 例对照)、GGLAD(1471 例,1482 例对照)和 MVP(9559 例,64 474 例对照)。研究发现,POAG 风险最高的五分之一人群的 OR 值增加,加纳人的 OR 值为 1.68(95% CI,1.17-2.43),而南非多祖先群体(至少来自 5 个不同的祖先群体:在南非多祖先群体(至少来自 5 个不同的祖先群体:科伊桑人、班图人、欧洲人、印度人和东南亚人)中,Gharahkhani PRS 的 OR 值为 7.05(95% CI)。汉族 PRS 显示,在 GGLAD 数据集中,POAG 风险最高的五分之一人群的 OR 增加,从非裔美国人的 2.27(95% CI,1.49-3.47)到欧洲人的 7.24(95% CI,6.47-8.12)不等。克雷格 PRS 预测 OR 在所有群体中的最高五分位数都会增加,从加纳人的 1.51(95% CI,1.05-2.18)到欧洲人的 6.31(95% CI,5.67-7.04)不等。然而,在 3 个测试的 PRS 中,所有非洲裔群体与欧洲裔群体相比,AUROC 和 R2 在基线以上的增幅较低:在这项横断面研究中,尽管使用 Gharahkhani PRSs、Han PRSs 和 Craig PRSs 进行基于 OR 的风险分层有所改善,但与欧裔血统群体相比,非洲裔血统群体的 AUROC 和 R2 的改善幅度一直较低,这突出表明需要为不同人群量身定制风险预测模型。
{"title":"Performance of Polygenic Risk Scores for Primary Open-Angle Glaucoma in Populations of African Descent.","authors":"Jennifer M Chang-Wolf, Tyler G Kinzy, Sjoerd J Driessen, Lauren A Cruz, Sudha K Iyengar, Neal S Peachey, Tin Aung, Chiea Chuen Khor, Susan E Williams, Michele Ramsay, Olusola Olawoye, Adeyinka Ashaye, Caroline C W Klaver, Michael A Hauser, Alberta A H J Thiadens, Jessica N Cooke Bailey, Pieter W M Bonnemaijer","doi":"10.1001/jamaophthalmol.2024.4784","DOIUrl":"10.1001/jamaophthalmol.2024.4784","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Primary open-angle glaucoma (POAG) polygenic risk scores (PRSs) continue to be evaluated in primarily European-ancestry populations despite higher prevalence and worse outcomes in African-ancestry populations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate how established POAG PRSs perform in African-ancestry samples from the Genetics in Glaucoma Patients of African Descent (GIGA), Genetics of Glaucoma in Individuals of African Descent (GGLAD), and Million Veteran Program (MVP) datasets and compare these with European-ancestry samples.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This was a multicenter, cross-sectional study of POAG cases and controls from Tanzania, South Africa, Nigeria, Ghana, and the US. Included were individuals of African descent from South Africa and Tanzania from the GIGA dataset; individuals of African descent from Ghana, Nigeria, and the US from the GGLAD dataset; and individuals of African or European descent from the US in the MVP dataset. Data were analyzed from January 2022 to July 2023.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposures: &lt;/strong&gt;Three PRSs derived from large meta-analyses of European and Asian populations, namely Gharahkhani et al (Gharahkhani PRS), Han et al (Han PRS), and Craig et al (Craig PRS).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Odds ratios (ORs) for POAG risk stratification comparing the highest and lowest quintiles; area under the receiver operating characteristic curve (AUROC), and liability coefficient of determination (R2) for the addition of PRS to a baseline of age, sex, and first 5 principal components.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 11 673 cases and 66 432 controls were included in this study across 7 ancestral groups. Mean (SD) age of the total participants was 76.9 (8.7) years, with 74 304 males (95.1%). The following were included in each dataset: GIGA (663 cases, 476 controls), GGLAD (1471 cases, 1482 controls), and MVP (9559 cases, 64 474 controls). Increases in ORs were found for the highest POAG risk quintile ranging from an OR of 1.68 (95% CI, 1.17-2.43) in Ghanaians to 7.05 (95% CI, 2.73-19.6) in the South African multiple ancestry group (which derives from at least 5 distinct ancestral groups: Khoisan, Bantus, Europeans, Indians, and Southeast Asians) with the Gharahkhani PRS. The Han PRS showed OR increases for the highest POAG risk quintile ranging from 2.27 (95% CI, 1.49-3.47) in African American individuals in the GGLAD dataset to 7.24 (95% CI, 6.47-8.12) in Europeans. The Craig PRS predicted OR increases in the highest quintile for all groups ranging from 1.51 (95% CI, 1.05-2.18) in Ghanaians to 6.31 (95% CI, 5.67-7.04) in Europeans. However, AUROC and R2 increases above baseline were lower for all African-ancestry compared with European-ancestry groups in the 3 tested PRSs.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In this cross-sectional study, despite some improvements in OR-based risk stratification using the Ghara","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"7-14"},"PeriodicalIF":7.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel In-Office Procedure for Retinal Detachment. 视网膜脱离的新手术方法。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamaophthalmol.2024.5491
Jacob S Heng, Yannis M Paulus
{"title":"Novel In-Office Procedure for Retinal Detachment.","authors":"Jacob S Heng, Yannis M Paulus","doi":"10.1001/jamaophthalmol.2024.5491","DOIUrl":"10.1001/jamaophthalmol.2024.5491","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"60-61"},"PeriodicalIF":7.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diabetic Retinopathy-Another Possible Target for SGLT2 Inhibitors? 糖尿病视网膜病变- SGLT2抑制剂的另一个可能靶点?
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamaophthalmol.2024.5364
Jonathan E Shaw, Alicia J Jenkins
{"title":"Diabetic Retinopathy-Another Possible Target for SGLT2 Inhibitors?","authors":"Jonathan E Shaw, Alicia J Jenkins","doi":"10.1001/jamaophthalmol.2024.5364","DOIUrl":"10.1001/jamaophthalmol.2024.5364","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"71-72"},"PeriodicalIF":7.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAMA Ophthalmology. JAMA眼科。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamaophthalmol.2024.4154
{"title":"JAMA Ophthalmology.","authors":"","doi":"10.1001/jamaophthalmol.2024.4154","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2024.4154","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"143 1","pages":"4"},"PeriodicalIF":7.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Visual Deficits in Patients With Mild Traumatic Brain Injury. 轻度脑外伤患者的视觉障碍。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamaophthalmol.2024.5121
Madeleine K Nowak, Francesca C Fortenbaugh, David H Salat
{"title":"Visual Deficits in Patients With Mild Traumatic Brain Injury.","authors":"Madeleine K Nowak, Francesca C Fortenbaugh, David H Salat","doi":"10.1001/jamaophthalmol.2024.5121","DOIUrl":"10.1001/jamaophthalmol.2024.5121","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"43-44"},"PeriodicalIF":7.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strongyloides stercoralis Choroiditis. 盘尾丝虫脉络膜炎
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamaophthalmol.2024.5104
Madelynn Corda, Jonathan Shepherd, Alan D Proia
{"title":"Strongyloides stercoralis Choroiditis.","authors":"Madelynn Corda, Jonathan Shepherd, Alan D Proia","doi":"10.1001/jamaophthalmol.2024.5104","DOIUrl":"10.1001/jamaophthalmol.2024.5104","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"83-85"},"PeriodicalIF":7.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-Office Suprachoroidal Viscopexy for Acute Rhegmatogenous Retinal Detachment. 急性孔源性视网膜脱离的脉络膜上粘连术。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamaophthalmol.2024.5202
Rajeev H Muni, Isabela Martins Melo, Sueellen Demian, Tomas Minelli, Hatim Batawi, John Park, Aurora Pecaku

Importance: In-office suprachoroidal viscopexy (SCVEXY) is a relatively new procedure for rhegmatogenous retinal detachment (RRD), but minimal information is available regarding outcomes and safety.

Objective: To report outcomes with in-office SCVEXY for primary acute RRD.

Design, setting, and participants: This retrospective case series was conducted at St Michael's Hospital in Toronto, Ontario, Canada from June 2023 to February 2024 among consecutive patients with primary acute RRDs who presented with retinal tears that were reachable with the current in-office SCVEXY technique in the temporal or nasal retina.

Exposure: Suprachoroidal injection of 0.6 mL of sodium hyaluronate, 2.3%, at the break location using a 30-gauge needle with a custom-made guard leaving 1 mm of the needle exposed. Laser retinopexy was applied around the break once reattachment was achieved.

Main outcome and measures: The primary outcome was primary anatomic reattachment rate with SCVEXY and recovery of function and anatomic integrity.

Results: Among 6 patients, 2 patients (33.3%) were female, and mean (SD) patient age was 52.5 (19.7) years. The final follow-up duration for each patient was 510, 420, 360, 360, 330, and 320 days, respectively. Baseline VAs were hand motions, counting fingers, 20/100, 20/100, 20/25, and hand motions for patients 1 through 6, respectively. A dome-shaped suprachoroidal buckle was present in all cases after the procedure. Five of 6 patients (83.3%) achieved anatomic reattachment with no retinal displacement or outer retinal folds, and these patients could resume normal activity immediately after the procedure with no restrictions. The mean (SD) logMAR VA at 3 months was +0.46 (0.34) (Snellen 20/57). The viscoelastic persisted in the suprachoroidal space as confirmed by multimodal imaging for 10, 14, 21, 13, 24, and 14 days, respectively, and the retina remained attached during the entire postoperative follow-up period. One patient's SCVEXY failed due to inadequate viscoelastic at the posterior edge of the retinal break, and this patient underwent a successful pneumatic retinopexy. One patient developed a localized choroidal effusion unrelated to the SCVEXY site following laser retinopexy that resolved in 1 week associated with topical prednisolone, 1%, 4 times daily and cyclopentolate, 1%, twice daily.

Conclusions and relevance: In this case series, the outcomes of these 6 cases suggest that SCVEXY may offer durable retinal reattachment in RRD. However, randomized clinical trial data, larger sample sizes, and longer-term follow-up are necessary to assess the risk-benefit profile of SCVEXY compared with the standard of care.

重要性:脉络膜上粘连术(SCVEXY)是治疗孔源性视网膜脱离(RRD)的一种相对较新的方法,但关于其疗效和安全性的信息很少。目的:报告使用SCVEXY治疗原发性急性RRD的结果。设计、环境和参与者:本回顾性病例系列研究于2023年6月至2024年2月在加拿大安大略省多伦多的圣迈克尔医院进行,研究对象为原发性急性rrd患者,这些患者均出现视网膜撕裂,目前的SCVEXY技术可在颞部或鼻视网膜上获得视网膜撕裂。暴露:使用带特制护套的30号针头在断口处注射0.6 mL透明质酸钠,2.3%,暴露针头1mm。一旦复位成功,在骨折周围应用激光视网膜固定术。主要观察指标:主要观察指标为SCVEXY的解剖再附着率、功能恢复和解剖完整性。结果:6例患者中,女性2例(33.3%),平均(SD)年龄为52.5(19.7)岁。每位患者的最终随访时间分别为510、420、360、360、330和320天。基线VAs分别为患者1至6的手部运动、数手指、20/100、20/100、20/25和手部运动。手术后所有病例均出现圆顶状脉络膜上扣。6例患者中有5例(83.3%)实现解剖复位,无视网膜移位或视网膜外褶皱,术后可立即恢复正常活动,无任何限制。3个月时的平均(SD) logMAR VA为+0.46 (0.34)(Snellen 20/57)。多模态成像证实,黏弹性分别在脉络膜上间隙持续了10、14、21、13、24和14天,视网膜在整个术后随访期间均保持附着。一名患者的SCVEXY由于视网膜断裂后缘粘弹性不足而失败,该患者接受了成功的充气视网膜固定术。1例患者在激光视网膜固定术后出现与SCVEXY部位无关的局部脉络膜积液,该积液在1周内解决,并局部应用1%泼尼松龙,每日4次和1%环戊酸盐,每日2次。结论和相关性:在本病例系列中,这6例病例的结果表明SCVEXY可以在RRD中提供持久的视网膜再植。然而,需要随机临床试验数据、更大的样本量和更长期的随访来评估SCVEXY与标准治疗相比的风险-收益情况。
{"title":"In-Office Suprachoroidal Viscopexy for Acute Rhegmatogenous Retinal Detachment.","authors":"Rajeev H Muni, Isabela Martins Melo, Sueellen Demian, Tomas Minelli, Hatim Batawi, John Park, Aurora Pecaku","doi":"10.1001/jamaophthalmol.2024.5202","DOIUrl":"10.1001/jamaophthalmol.2024.5202","url":null,"abstract":"<p><strong>Importance: </strong>In-office suprachoroidal viscopexy (SCVEXY) is a relatively new procedure for rhegmatogenous retinal detachment (RRD), but minimal information is available regarding outcomes and safety.</p><p><strong>Objective: </strong>To report outcomes with in-office SCVEXY for primary acute RRD.</p><p><strong>Design, setting, and participants: </strong>This retrospective case series was conducted at St Michael's Hospital in Toronto, Ontario, Canada from June 2023 to February 2024 among consecutive patients with primary acute RRDs who presented with retinal tears that were reachable with the current in-office SCVEXY technique in the temporal or nasal retina.</p><p><strong>Exposure: </strong>Suprachoroidal injection of 0.6 mL of sodium hyaluronate, 2.3%, at the break location using a 30-gauge needle with a custom-made guard leaving 1 mm of the needle exposed. Laser retinopexy was applied around the break once reattachment was achieved.</p><p><strong>Main outcome and measures: </strong>The primary outcome was primary anatomic reattachment rate with SCVEXY and recovery of function and anatomic integrity.</p><p><strong>Results: </strong>Among 6 patients, 2 patients (33.3%) were female, and mean (SD) patient age was 52.5 (19.7) years. The final follow-up duration for each patient was 510, 420, 360, 360, 330, and 320 days, respectively. Baseline VAs were hand motions, counting fingers, 20/100, 20/100, 20/25, and hand motions for patients 1 through 6, respectively. A dome-shaped suprachoroidal buckle was present in all cases after the procedure. Five of 6 patients (83.3%) achieved anatomic reattachment with no retinal displacement or outer retinal folds, and these patients could resume normal activity immediately after the procedure with no restrictions. The mean (SD) logMAR VA at 3 months was +0.46 (0.34) (Snellen 20/57). The viscoelastic persisted in the suprachoroidal space as confirmed by multimodal imaging for 10, 14, 21, 13, 24, and 14 days, respectively, and the retina remained attached during the entire postoperative follow-up period. One patient's SCVEXY failed due to inadequate viscoelastic at the posterior edge of the retinal break, and this patient underwent a successful pneumatic retinopexy. One patient developed a localized choroidal effusion unrelated to the SCVEXY site following laser retinopexy that resolved in 1 week associated with topical prednisolone, 1%, 4 times daily and cyclopentolate, 1%, twice daily.</p><p><strong>Conclusions and relevance: </strong>In this case series, the outcomes of these 6 cases suggest that SCVEXY may offer durable retinal reattachment in RRD. However, randomized clinical trial data, larger sample sizes, and longer-term follow-up are necessary to assess the risk-benefit profile of SCVEXY compared with the standard of care.</p>","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"53-60"},"PeriodicalIF":7.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Error in Text and Table. 文本和表格错误。
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamaophthalmol.2024.5503
{"title":"Error in Text and Table.","authors":"","doi":"10.1001/jamaophthalmol.2024.5503","DOIUrl":"10.1001/jamaophthalmol.2024.5503","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"85"},"PeriodicalIF":7.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11622063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Looking Beyond and Behind a Retinal Detachment. 透视视网膜脱离背后的真相
IF 7.8 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamaophthalmol.2024.5001
Shahriyar P Majidi, Ashley A Campbell, Bryn Burkholder
{"title":"Looking Beyond and Behind a Retinal Detachment.","authors":"Shahriyar P Majidi, Ashley A Campbell, Bryn Burkholder","doi":"10.1001/jamaophthalmol.2024.5001","DOIUrl":"10.1001/jamaophthalmol.2024.5001","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"80-81"},"PeriodicalIF":7.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1